#1 Clinical Trials Search in Europe

Nacubactam

Nacubactam is an innovative drug currently being studied in clinical trials for the treatment of serious bacterial infections. This article explores the ongoing research into Nacubactam’s effectiveness, safety, and potential applications in combating various types of infections, particularly those caused by antibiotic-resistant bacteria.

Table of Contents

What is Nacubactam?

Nacubactam, also known as RO7079901, is a new antibiotic medication currently being studied for the treatment of serious bacterial infections[1]. It belongs to a class of drugs called beta-lactamase inhibitors, which are designed to work alongside other antibiotics to make them more effective against resistant bacteria.

How Does Nacubactam Work?

Nacubactam is a non-beta-lactam beta-lactamase inhibitor. This means it helps prevent bacteria from breaking down certain antibiotics, allowing those antibiotics to work more effectively[1]. It is being developed to be used in combination with other antibiotics, particularly:

  • Meropenem: A powerful antibiotic used to treat a wide range of bacterial infections[1]
  • Cefepime: An antibiotic used to treat various bacterial infections[2]
  • Aztreonam: An antibiotic specifically used against gram-negative bacteria[2]

By combining nacubactam with these antibiotics, researchers hope to create more effective treatments for difficult-to-treat bacterial infections, especially those caused by antibiotic-resistant bacteria.

What Conditions Can Nacubactam Treat?

Nacubactam is being studied for the treatment of several serious bacterial infections, including[2][3]:

  • Complicated Urinary Tract Infections (cUTI): These are urinary tract infections that are more difficult to treat, often due to structural abnormalities in the urinary tract or the presence of resistant bacteria.
  • Acute Pyelonephritis (AP): This is a serious kidney infection that can occur when a urinary tract infection spreads to one or both kidneys.
  • Hospital-Acquired Bacterial Pneumonia (HABP): This is a lung infection that develops during a hospital stay, often in patients who are on ventilators.
  • Ventilator-Associated Bacterial Pneumonia (VABP): This is a type of pneumonia that occurs in patients who are on mechanical ventilation.
  • Complicated Intra-Abdominal Infections (cIAI): These are infections that extend beyond the hollow organ of origin into the peritoneal space, often requiring both surgical and antibiotic treatment.

Importantly, nacubactam is being specifically developed to target infections caused by Carbapenem-Resistant Enterobacterales (CRE)[2]. These are a group of bacteria that have developed resistance to many commonly used antibiotics, making them particularly challenging to treat.

How is Nacubactam Administered?

Nacubactam is administered intravenously (through a vein) in combination with other antibiotics. In clinical trials, it is typically given as follows[1][2][3]:

  • A dose of 1 gram (g) of nacubactam is given along with 2 g of the partner antibiotic (meropenem, cefepime, or aztreonam)
  • The medication is given every 8 hours
  • Each dose is infused over a period of 60-90 minutes
  • Treatment typically lasts for at least 5 days and up to 14 days, depending on the type and severity of the infection

Current Clinical Trials

Nacubactam is currently being studied in several clinical trials to evaluate its safety and effectiveness. These trials include[1][2][3]:

  1. A study investigating how well nacubactam penetrates into the lungs when given with meropenem
  2. A large Phase 3 trial comparing nacubactam (given with either cefepime or aztreonam) to the best available therapy for infections caused by carbapenem-resistant bacteria
  3. Another Phase 3 trial comparing nacubactam (with cefepime or aztreonam) to imipenem/cilastatin for treating complicated urinary tract infections and acute pyelonephritis

These trials are designed to measure various outcomes, including how well the drug combination clears the infection, how it compares to existing treatments, and how safe it is for patients.

Safety and Side Effects

As nacubactam is still in clinical trials, comprehensive information about its safety profile and potential side effects is not yet available. However, the ongoing studies are carefully monitoring for any adverse events[1].

An adverse event in clinical trials is defined as any unfavorable and unintended sign, symptom, or disease that occurs during the study, whether or not it’s considered related to the drug being tested. This could include changes in laboratory test results, new symptoms, or worsening of pre-existing conditions.

It’s important to note that all medications can potentially cause side effects, and the benefits of treatment need to be weighed against any risks. As nacubactam progresses through clinical trials, more information about its safety and potential side effects will become available.

Aspect Details
Drug Name Nacubactam (also known as RO7079901)
Drug Class Non-beta-lactam beta-lactamase inhibitor
Combination Therapies Studied with meropenem, cefepime, and aztreonam
Target Infections Gram-negative bacterial infections, including CRE infections
Specific Conditions Studied cUTI, AP, HABP, VABP, cIAI
Administration Method Intravenous infusion
Key Study Objectives Efficacy, safety, lung penetration, pharmacokinetics
Comparators in Trials Best Available Therapy, Imipenem/Cilastatin
Trial Phases Phase 3 studies ongoing

FAQ

  • What is Nacubactam? Nacubactam is a novel non-beta-lactam beta-lactamase inhibitor being developed as a combination therapy with other antibiotics, such as meropenem, cefepime, or aztreonam, for treating serious gram-negative bacterial infections.
  • What types of infections is Nacubactam being tested for? Nacubactam is being studied for various infections, including complicated urinary tract infections, acute pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, and complicated intra-abdominal infections.
  • How is Nacubactam administered? In the clinical trials, Nacubactam is typically administered as an intravenous (IV) infusion, often in combination with other antibiotics. The dosage and duration may vary depending on the specific study and infection type.
  • What makes Nacubactam different from other antibiotics? Nacubactam is unique because it's a beta-lactamase inhibitor, which means it can help other antibiotics work better against resistant bacteria. It's being studied in combination with various antibiotics to potentially overcome antibiotic resistance.
  • Are there any known side effects of Nacubactam? While the full safety profile is still being studied, the clinical trials are monitoring for adverse events. As with any medication, there may be potential side effects, but specific information is not yet available from the provided trial data.

Ongoing Clinical Trials on Nacubactam

  • Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Resistant Bacterial Infections

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Croatia Czechia France Greece Latvia Slovakia +1

  • Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Bulgaria Czechia Estonia Latvia Lithuania Slovakia

Glossary

  • Beta-lactamase inhibitor: A substance that blocks the action of beta-lactamase enzymes, which some bacteria produce to resist certain antibiotics. By inhibiting these enzymes, beta-lactamase inhibitors can make antibiotics more effective against resistant bacteria.
  • Gram-negative bacteria: A group of bacteria that do not retain crystal violet dye in the Gram staining method. They can cause various infections and are often more resistant to antibiotics than gram-positive bacteria.
  • Carbapenem-resistant Enterobacterales (CRE): A group of bacteria that are resistant to carbapenem antibiotics, which are often considered a last resort for treating serious infections. CRE infections can be very difficult to treat.
  • Complicated Urinary Tract Infection (cUTI): A urinary tract infection that is associated with factors that increase the risk of failing therapy, such as structural or functional abnormalities of the urinary tract.
  • Acute Pyelonephritis (AP): A sudden and severe kidney infection, usually caused by bacteria traveling up from the bladder to the kidney.
  • Hospital-Acquired Bacterial Pneumonia (HABP): A type of pneumonia that develops 48 hours or more after hospital admission and was not incubating at the time of admission.
  • Ventilator-Associated Bacterial Pneumonia (VABP): A type of pneumonia that develops in patients who have been on mechanical ventilation for at least 48 hours.
  • Complicated Intra-Abdominal Infection (cIAI): An infection that extends beyond the hollow organ of origin into the peritoneal space and is associated with abscess formation or peritonitis.
  • Epithelial Lining Fluid (ELF): The thin layer of fluid that coats the lung's airways. In clinical trials, ELF concentration is used to measure how well a drug penetrates into the lungs.
  • Bronchoalveolar Lavage (BAL): A medical procedure where a bronchoscope is passed through the mouth or nose into the lungs and fluid is squirted into a small part of the lung and then recollected for examination.

References